Evidence map›Paper›PMID 35788695›Full record

ArticleCommunications biology2022

Antimicrobial strategy for targeted elimination of different microbes, including bacterial, fungal and viral pathogens.

Makoto Mitsunaga, Kimihiro Ito, Takashi Nishimura, Hironori Miyata, Kei Miyakawa, Takeshi Morita, Akihide Ryo, Hisataka Kobayashi, Yoshimitsu Mizunoe, Tadayuki Iwase

Abstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Near-Infrared Dyes: Towards Broad-Spectrum Antivirals.International journal of molecular sciences · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Makoto Mitsunaga *Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. mit@jikei.ac.jp.ORCID http://orcid.org/0000-0002-8229-5134
Kimihiro Ito *Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Takashi NishimuraDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hironori MiyataAnimal Research Center, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kei MiyakawaDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
Takeshi MoritaDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
Akihide RyoDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
Hisataka KobayashiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-1019-4112
Yoshimitsu MizunoeThe Jikei University School of Medicine, Tokyo, Japan.
Tadayuki IwaseResearch Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan. iwase.tadayuki@jikei.ac.jp.ORCID http://orcid.org/0000-0003-4915-3983

Funding

Activatable molecular cancer imaging probeZIABC011512 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$2.7M
6 · The paper itself

Abstract

The continuous emergence of microbial pathogens for which there are no effective antimicrobials threatens global health, necessitating novel antimicrobial approaches. Here, we present a targeted antimicrobial strategy that can be applied to various microbial pathogens. A photoimmuno-conjugate composed of an antibody against the target pathogen and a photoplastic phthalocyanine-derivative probe that generates photo-induced mechanical stress was developed based on photoimmuno-technology. This strategy, named as photoimmuno-antimicrobial strategy (PIAS), eliminates targeted pathogens, regardless of the target species or drug-resistance status. Specifically, PIAS acts on a broad range of microbes, including the bacterial pathogen Staphylococcus aureus, fungal pathogen Candida albicans, including their drug-resistant strains, and viral pathogen SARS-CoV-2, the causative agent of COVID-19. Furthermore, PIAS protects mice from fatal infections without damaging the non-targeted host microbiota and tissues. This study may contribute to the development of next-generation anti-infective therapies.

Indexed as

Anti-Infective AgentsCOVID-19 Drug TreatmentAnimalsAnti-Bacterial AgentsBacteriaMiceSARS-CoV-2Anti-Bacterial AgentsAnti-Infective Agents

Identifiers

PMID35788695
PMCPMC9253063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.